Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
CJC-1295: Long-acting GHRH analog that increases baseline GH levels Ipamorelin: Growth hormone secretagogue that creates GH pulses without affecting cortisol or prolactin Combined benefits: Increased lean muscle mass (5-10 pounds over 3-6 months) Enhanced fat loss (especially visceral fat) Improved recovery between training sessions Better sleep quality (GH release during deep sleep) Increased collagen synthesis (joint/tendon health) Enhanced overall body composition Dosing: CJC-1295: 200-300mcg Ipamorelin: 200-300mcg Inject together, subcutaneously, before bed 5-7 days per week Timeline: Improved sleep within 1-2 weeks Better recovery within 3-4 weeks Visible body composition changes 8-12 weeks Maximum benefits 4-6 months Best for: Men wanting lean muscle gains, improved recovery, and overall body composition optimization without the risks of growth hormone itself
Gastroenterology 159 , 944955.e8 (2020)
Use progressive overload: increase load or reps gradually to counteract metabolic adaptation
